Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05647122 · ClinicalTrials.gov registry record · Phase 1
First in Human Study of AZD9592 in Solid Tumors
A Phase 1 study of Carcinoma, Non-Small Cell Lung and Colorectal Neoplasms, sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 403
- Enrollment target
- 20
- Study locations
NCT05647122: Recruiting Phase 1 study of Carcinoma, Non-Small Cell Lung and Colorectal Neoplasms, sponsored by AstraZeneca.
NCT05647122 is a Phase 1 study of Carcinoma, Non-Small Cell Lung and Colorectal Neoplasms that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 403 participants, above the 321-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (26% higher). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05647122, a Phase 1 study of Carcinoma, Non-Small Cell Lung and Colorectal Neoplasms, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 403 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a first-in-human (FIH) Phase I, multi-center, open-label, study of AZD9592, in patients with advanced solid tumors. The study consists of several study modules, each evaluating the safety, tolerability, preliminary efficacy, pharmacokinetics (PK), pharmacodynamics, anti-tumor activity, and immunogenicity of AZD9592, as monotherapy or in combination with anti-cancer agents.
Primary Outcome
Number of patients with adverse events by system organ class and preferred term
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Osimertinib
- DRUG Leucovorin
- DRUG 5-Fluorouracil (5-FU)
- DRUG AZD9592
Study Locations (20)
New York
- Research Site - Mineola
- Research Site - New York
- Research Site - New York
- Research Site - New York
California
- Research Site - Duarte
- Research Site - Irvine
Maryland
- Research Site - Baltimore
- Research Site - Baltimore
Other
- Research Site - Kogarah
- Research Site - Melbourne
Connecticut
- Research Site - North Haven
District of Columbia
- Research Site - Washington D.C.
Illinois
- Research Site - Chicago
Massachusetts
- Research Site - Milford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 403 participants |
| Start Date | 2022-12-21 |
| Est. Completion | 2027-10-06 |
| Phase | Phase 1 |
What NCT05647122 shows while recruiting
NCT05647122 is an interventional study that assigns participants to a tested intervention. The registered 403 participants enrollment target is mid-sized for trials with a published cap, above the 321-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (26% higher).
The record links to 4 conditions, with Carcinoma, Non-Small Cell Lung appearing as the primary indexed condition, and to 5 interventions - of which Bevacizumab is the first listed.
NCT05647122 names 20 study sites across 14 states, led by New York, California, Maryland.
Frequently Asked Questions
What is clinical trial NCT05647122 about?
NCT05647122 is a clinical study titled "First in Human Study of AZD9592 in Solid Tumors". This is a first-in-human (FIH) Phase I, multi-center, open-label, study of AZD9592, in patients with advanced solid tumors. The study consists of several study modules, each evaluating the safety, tolerability, preliminary efficacy, pharmacokinetics (PK), pharmacodynamics, anti-tumor activity, and i...
What is the current status of trial NCT05647122?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 403 participants. The study started on 2022-12-21. Estimated completion is 2027-10-06.
What conditions does trial NCT05647122 study?
This clinical trial studies the following conditions: Carcinoma, Non-Small Cell Lung, Colorectal Neoplasms, Head and Neck Neoplasms, Advanced Solid Tumours.
What interventions are being tested in trial NCT05647122?
The interventions under investigation include: Bevacizumab (DRUG), Osimertinib (DRUG), Leucovorin (DRUG), 5-Fluorouracil (5-FU) (DRUG), AZD9592 (DRUG).
Who is sponsoring clinical trial NCT05647122?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05647122 being conducted?
This trial has 20 study locations across California, Connecticut, District of Columbia, Illinois, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carcinoma, Non-Small Cell Lung
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05647122's enrollment target sits among peer trials
403 34th of 130 higher than 97 of 130 other Carcinoma, Non-Small Cell Lung trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Carcinoma, Non-Small Cell Lung trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
RECRUITING · Phase 1
-
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
RECRUITING · Phase 1
-
A Study of LY4175408 in Participants With Advanced Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05674799 · 403 participants · NA
NDPP-NextGen: A Clinical Trial to Reduce Intergenerational Obesity and Diabetes Risks
- NCT06244771 · 403 participants · Phase 1
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
- NCT05049057 · 404 participants · Phase 2
Treatment of Acute PTH With a CGRP Receptor mAb in Military Service Members and Civilians With mTBI
- NCT05611242 · 404 participants · Phase 3
Proximal Internal Carotid Artery Acute Stroke Secondary to Tandem or Local Occlusion Thrombectomy Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI